Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2231 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2231 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase II
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
A trial testing ALN-6400 injections to reduce heavy menstrual bleeding in women and girls with von Willebrand disease.
26 Oct 2026 NCT07575308
● Recruiting Phase I / Phase II Diabetes / Metabolic
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
WVE-007 is a new injectable weight-loss drug being tested for safety and effectiveness in overweight and obese adults, with and without type 2 diabetes.
26 Oct 2026 NCT06842186
● Recruiting Phase II Oncology
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
26 Oct 2026 NCT06942442
● Recruiting Phase II Respiratory / COPD / Asthma
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer’s Disease
What is being tested: SAR448851, a novel once-daily oral medication, is being evaluated in a randomized, placebo-controlled Phase 2 trial to assess its efficacy…
23 Oct 2026 NCT07688213
● Recruiting Phase II Neurology
Prevent Cognitive Decline in GBA-associated Parkinson’s Disease
Treatment being tested: Prasinezumab, a monoclonal antibody, is being evaluated for its ability to slow or prevent cognitive decline in patients with Parkinson's disease…
23 Oct 2026 NCT07055087
active not recruiting Phase II
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Bezuclastinib plus standard care improved symptoms better than placebo in patients with indolent or smoldering systemic mastocytosis.
22 Oct 2026 NCT05186753
● Recruiting Phase II
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
A drug called INCB000928 is tested against placebo in patients with fibrodysplasia ossificans progressiva to assess its effectiveness and safety.
22 Oct 2026 NCT05090891
● Recruiting Phase II Respiratory / COPD / Asthma
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Treatment being tested: PF-07275315, a novel investigational medicine, is being evaluated for efficacy and safety in patients with moderate to severe COPD to address…
22 Oct 2026 NCT07363694
● Recruiting Phase II Oncology
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
What is being tested: The combination of two immunotherapy agents—porustobart and pembrolizumab—administered before surgery (neoadjuvant approach) in patients with resectable, microsatellite stable/proficient mismatch repair…
22 Oct 2026 NCT07808151
active not recruiting Phase I / Phase II Oncology
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BT8009-100 Trial Summary First-in-human trial testing BT8009 alone and with pembrolizumab in advanced cancers expressing Nectin-4 protein.
20 Oct 2026 NCT04561362
● Recruiting Phase II Oncology
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to…
20 Oct 2026 NCT06607458
● Recruiting Phase II Rheumatology
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
SKYPS Trial Summary Sarilumab dose-finding study in children with systemic juvenile idiopathic arthritis to establish safe, effective dosing and assess safety outcomes.
19 Oct 2026 NCT02991469
● Recruiting Phase II Oncology
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to…
19 Oct 2026 NCT06875128
● Recruiting Phase II Respiratory / COPD / Asthma
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants…
16 Oct 2026 NCT07516951
● Recruiting Phase II Oncology
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked,…
16 Oct 2026 NCT06782373
● Recruiting Phase II Respiratory / COPD / Asthma
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
This study will evaluate the impact Nintedanib Solution for Inhalation (AP02) has on lung function and key measures of fibrosis in adult patients with…
15 Oct 2026 NCT07194382
● Recruiting Phase II Cardiology / Cardiovascular
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses…
15 Oct 2026 NCT07830719
● Recruiting Phase II Cardiology / Cardiovascular
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.…
15 Oct 2026 NCT06321302
● Recruiting Phase II Mental Health / Psychiatry
ALTO-100 in Bipolar Disorder With Depression (BD-D)
ALTO-100 tested against placebo for treating depression in bipolar disorder patients already on mood stabilizers or antipsychotics.
13 Oct 2026 NCT06656416
● Recruiting Phase II / Phase III Gastroenterology
A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy
GNT0004 is a one-time gene therapy delivering a functional dystrophin gene to slow Duchenne muscular dystrophy progression.
13 Oct 2026 NCT07856329
active not recruiting Phase II Gastroenterology
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
MAS825 tested as treatment for rare genetic inflammatory disorders caused by NLRC4, XIAP, or CDC42 mutations.
09 Oct 2026 NCT04641442
● Recruiting Phase II Oncology
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
What is being tested: Alpelisib (a PI3K inhibitor) administered as film-coated tablets in pediatric and adult patients with lymphatic malformations (LyM) caused by PIK3CA…
09 Oct 2026 NCT05948943
active not recruiting Phase II / Phase III
Setrusumab vs Placebo for Osteogenesis Imperfecta
Setrusumab (an antibody) reduces fractures in osteogenesis imperfecta patients compared to placebo.
06 Oct 2026 NCT05125809
active not recruiting Phase II Respiratory / COPD / Asthma
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Inhaled pirfenidone added to standard care slowed lung decline in progressive pulmonary fibrosis patients over one year.
05 Oct 2026 NCT06329401
● Recruiting Phase II Oncology
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
What is being tested: Inebilizumab, a monoclonal antibody targeting B cells, is being evaluated for its pharmacokinetics, pharmacodynamics, safety, and tolerability in children with…
05 Oct 2026 NCT06987539
● Recruiting Phase II
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
TYRA-300 trial tests safety and effective doses of a new treatment for children with achondroplasia who still have growing bones.
01 Oct 2026 NCT06842355
active not recruiting Phase II Gastroenterology
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
A trial testing whether a drug called elafibranor can safely treat primary sclerosing cholangitis, a rare liver disease.
01 Oct 2026 NCT05627362
active not recruiting Phase II / Phase III
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE103 compared with ranibizumab for diabetic macular swelling, initially monthly then personalised treatment intervals.
30 Sep 2026 NCT06571045
● Recruiting Phase II Oncology
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
What is being tested: AZD0901, a novel therapeutic agent, is being evaluated as both monotherapy and in combination with existing anti-cancer agents in patients…
30 Sep 2026 NCT06219941
active not recruiting Phase II Diabetes / Metabolic
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
Trial testing whether BI 3034701 injection helps weight loss in obese/overweight adults over ten months.
29 Sep 2026 NCT07662122
● Recruiting Phase II Respiratory / COPD / Asthma
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Treatment being tested: Brenipatide (LY3537031), a novel therapeutic agent, is being evaluated at multiple dose levels versus placebo to assess safety and efficacy in…
25 Sep 2026 NCT07759245
● Recruiting Phase II Oncology
WIRE – Novel Treatments in Renal Cell Cancer
What is being tested: Novel immunomodulatory therapies (IMPs) administered as monotherapy or combination therapy in a "window of opportunity" period before surgical removal of…
25 Sep 2026 NCT03741426
● Recruiting Phase II Cardiology / Cardiovascular
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
What is being tested: Local perivenous delivery of dexamethasone using the Bullfrog® Micro-Infusion Device immediately after catheter-directed thrombus removal in acute femoropopliteal DVT to…
25 Sep 2026 NCT04862468
active not recruiting Phase II Rheumatology
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Trial testing whether a new drug (tulisokibart) reduces rheumatoid arthritis symptoms better than placebo in patients already taking methotrexate.
24 Sep 2026 NCT07176390
● Recruiting Phase II / Phase III
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Comparing two growth-boosting drugs (BMN 333 and vosoritide) in children with achondroplasia to see which works better and is safer.
24 Sep 2026 NCT07441876
● Recruiting Phase II Gastroenterology
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
A trial testing whether SAR444336 maintains remission in microscopic colitis patients already on budesonide treatment.
23 Sep 2026 NCT07156175
● Recruiting Phase II / Phase III Oncology
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Trial testing a new antibody drug combined with chemotherapy to treat high-risk neuroblastoma in young children.
23 Sep 2026 NCT07549321
● Recruiting Phase II Oncology
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Treatment being tested: Triple combination of visugromab (anti-VEGF-C monoclonal antibody), nivolumab (anti-PD-1), and lenvatinib (tyrosine kinase inhibitor) versus lenvatinib monotherapy plus placebo in treatment-resistant…
23 Sep 2026 NCT07219459
● Recruiting Phase I / Phase II
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Single eye injection of SAR446597 tested for safety and effectiveness in age-related macular degeneration vision loss over two years.
22 Sep 2026 NCT07215234
active not recruiting Phase II
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
Iptacopan tested to prevent progression of early-to-intermediate age-related macular degeneration to advanced vision loss.
22 Sep 2026 NCT05230537
active not recruiting Phase I / Phase II Oncology
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Early-stage trial testing whether AZD5305 PARP inhibitor works alone or combined with other cancer drugs in advanced solid tumors.
21 Sep 2026 NCT04644068
● Recruiting Phase II Cardiology / Cardiovascular
A-TANGO Phase 2 Study
What is being tested: A combination therapy of TAK-242 (a TLR4 antagonist) plus G-CSF (granulocyte-colony stimulating factor) added to standard ACLF treatment, compared to…
21 Sep 2026 NCT06890039
● Recruiting Phase II Cardiology / Cardiovascular
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
What is being tested: JX10, a novel therapeutic agent, is being evaluated against placebo in acute ischemic stroke patients to assess its safety and…
21 Sep 2026 NCT06990867
● Recruiting Phase II Oncology
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
What is being tested: Long-term safety and efficacy outcomes in pediatric and adult patients previously treated with gene-modified T-cell therapy through Celgene-sponsored clinical trials,…
18 Sep 2026 NCT03435796
● Recruiting Phase II Oncology
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
What is being tested: MEN1703 (SEL24/Dapolsertib hydrochloride), a novel agent being evaluated as monotherapy or in combination with glofitamab, assessing safety and anti-lymphoma activity…
18 Sep 2026 NCT06534437
● Recruiting Phase II / Phase III Infectious Disease
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
PLG0206 tested as wound irrigation during knee implant infection surgery to prevent reinfection and improve outcomes.
17 Sep 2026 NCT07214311
● Recruiting Phase II Respiratory / COPD / Asthma
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
A Phase 2b trial testing a single-dose vaccine against RSV and metapneumovirus in 8,000 adults aged 60+, measuring effectiveness, safety, and immune response.
16 Sep 2026 NCT07810010
● Recruiting Phase II Oncology
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Treatment being tested: VVD-133214 (a novel therapeutic agent) combined with pembrolizumab (an immune checkpoint inhibitor) versus pembrolizumab monotherapy in patients with advanced colorectal cancer,…
16 Sep 2026 NCT07811193
active not recruiting Phase I / Phase II Neurology
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer’s Disease
Study testing increasing doses of RO7126209 infusions to assess safety and effectiveness in early Alzheimer's disease patients with amyloid buildup.
14 Sep 2026 NCT04639050
active not recruiting Phase II Gastroenterology
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
A new drug called tilpisertib fosmecarbil tested against placebo in patients with moderate-to-severe ulcerative colitis to see if it improves symptoms by week 12.
11 Sep 2026 NCT06029972